Private Equity and Debt Placement – Life Sciences / Ag Biotech 
      Buy Side M&A Advisory – Life Sciences / Ag Biotech
   January 2008 

Stephens Inc. advised Inguran LLC, commonly known as Sexing Technologies, on the purchase of controlling interest in XY, Inc. with $28.5 million Series A Preferred Stock and a $5.0 million Standby Equity commitment. On November 20, 2007, Inguran completed a second closing of $11.5 million Preferred & Common Equity and $10.0 million in Subordinated Notes. The second closing provided capital to complete the merger. Stephens Inc. acted as financial advisor in connection with the transaction and acted as Inguran’s exclusive placement agent on the financing.